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A B S T R A C T
Carrier-based dry powder inhaler (DPI) formulations need to be accurately characterised for their particle size
distributions, surface roughnesses, fines contents and flow properties. Understanding the micro-structure of the
powder formulation is crucial, yet current characterisation methods give incomplete information. Commonly
used techniques like laser diffraction (LD) and optical microscopy (OM) are limited due to the assumption of
sphericity and can give variable results depending on particle orientation and dispersion. The aim of this work
was to develop new three dimensional (3D) powder analytical techniques using X-ray computed tomography
(XCT) that could be employed for non-destructive metrology of inhaled formulations. α-lactose monohydrate
powders with different characteristics have been analysed, and their size and shape (sphericity/aspect ratio)
distributions compared with results from LD and OM. The three techniques were shown to produce comparable
size distributions, while the different shape distributions from XCT and OM highlight the difference between 2D
and 3D imaging. The effect of micro-structure on flowability was also analysed through 3D measurements of void
volume and tap density. This study has demonstrated for the first time that XCT provides an invaluable, non-
destructive and analytical approach to obtain number- and volume-based particle size distributions of DPI
formulations in 3D space, and for unique 3D characterisation of powder micro-structure.
1. Introduction
Drug delivery to the lungs is a highly desirable but extremely
challenging field in pharmaceutical sciences. Pulmonary drug delivery
has the advantage of allowing targeted administration directly to air-
ways for local activity, or by delivery to the alveolar region for quick
absorption into the blood stream with rapid systematic onset [24,47].
The challenge is to engineer a drug formulation that can reach the deep
lungs in a portable dosage form that can be easily aerosolised and hence
administered when required [8].
Dry powder inhalers (DPIs) consist of a powder mixture of active
pharmaceutical ingredients (API) and inert carriers (excipients) con-
tained in a device that deagglomerates the particles upon inhalation to
deliver a dose to the lung [15]. The powder itself is central to the
performance of a DPI [22], and hence the powder microstructure has a
critical influence. Each of the physical particle attributes, such as size,
shape, morphology and surface roughness, has an impact on the powder
behaviour [34], together with the spatial organisation and correlation
between the particles.
The API particles are typically produced via micronisation to reach
the desirable size range of 1–5 μm required for inhalation. However,
such micronised particles are not easily dispersed upon inhalation as
they are highly cohesive and prone to agglomeration [13]. In order to
improve the flowability and dispersibility of the formulation, the API
fines are blended with larger coarse carrier particles, usually α-lactose
monohydrate with particle sizes >100 µm [49,64], while intrinsic lac-
tose fines can also be added to improve the aerosolisation performance
[23,26,31]. Upon inhalation, the coarse lactose carriers are more likely
to be deposited by inertial impaction in the oropharynx and upper re-
spiratory tract, while the micronised API aerosols can achieve deep lung
deposition. Aerosol deposition mechanisms have been reviewed ex-
tensively in the literature [9].
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DPIs are also heavily dependent on powder flow, through metering,
fluidisation and dispersion. The flow of the powders is linked to the
spatial organisation and correlation of the particles, which in turn is
influenced by the physical attributes of the carrier [43,47,54]. For ex-
ample, while a decrease in carrier size causes a decrease in the API-
carrier interactions and as such an increase in drug detachment [36],
the increased amounts of intrinsic carrier fines as a result of the carrier
communition result in reduced flowability [53]. At the same time, in-
creased carrier roughness can result in API fines fitting into cavities and
thus not readily dispersed upon inhalation [11]. Lactose properties and
their connections to DPI performance have been extensively reviewed
elsewhere [34,49] and are constantly under investigation. The con-
nection between particle properties and flow behaviour has also been
recently reviewed [6,55].
The most commonly used techniques for characterising physical
powder attributes are laser diffraction (LD), scanning electron micro-
scopy (SEM), optical microscopy (OM) and cascade impaction (CI), but
each have their own limitations; for example LD measurements provide
the volume-based particle size distribution, but suffer from shape-bias
[62] as the technique assumes spherical particles as opposed to the
tomahawk shape typical of lactose crystals [51]. Microscopy-based
techniques like SEM and OM are based on the 2D image analysis of
particles dispersed on a substrate to produce particle size distributions
and shape metrics such as aspect ratio and circularity. However, the
results are highly dependent on the crystal orientation on the substrate.
Another shared limitation of all these techniques is that they depend on
powder dispersion and are destructive. Yet despite these limitations,
LD, SEM, OM and CI have become the industrial standards for size and
shape characterisation due to the lack of a suitable alternative.
Microstructure can also be assessed when studying the fluidisation
and ease of dispersion of cohesive DPI powders. Particle image velo-
cimetry (PIV) [18] and fluorescent imaging [41] employ 2D cameras to
study the flow velocity and spatial distributions of API fines respec-
tively while LD airflow titration experiments have also been employed
to study the ease of de-agglomeration [5,25]. However, cohesiveness is
only an indirect indicator of the microstructure. A summary of the most
common characterisation techniques with their advantages and dis-
advantages is given in Table 1.
The most common indicator of the flowability of a powder is its
compressibility, which is typically measured by comparing the bulk
densities of a tapped and loosely packed powder column [65]. Other
methods for measuring powder flowability include the angle of repose,
or measuring the time taken to flow out of a funnel with a well-defined
orifice. Although flowability is a bulk metric, it is dependent on particle
level arrangements, with particle size and shape known to be influen-
cing factors [20,65]. None of these techniques provide any insight on
spatial organisation and correlation, and hence the ways in which
physical attributes affect flowability at the particle level. Ring shear
testers (RST) can be used to measure the flowability of a powder
through a flow function coefficient (ffc) whilst providing information on
the bulk cohesion and angle of friction [32,61]. Thus RST can also
provide a useful link between particle size & shape, and the powder
flow properties. SEM can provide some information about the particle-
particle contacts but this is limited to a 2D projection.
The sample-destructive nature of the aforementioned techniques,
their shape-assumptions as well as their 2D-based description are well-
known deficiencies. The need to fully characterise the microstrucure of
DPI formulations has recently become more important due to the in-
troduction of “microstructural equivalence” from the Food and Drug
Administration (FDA) [35,37,50]. To this end, X-ray computed tomo-
graphy (XCT) [19,39] has increasingly gained interest as a non-de-
structive technique to study the microstructure of pharmaceutical for-
mulations.
XCT is well-established in the fields of material and medical sciences
[38,63], and the general principles are shown in Fig. 1. An X-ray source
illuminates the sample with X-rays and the transmitted X-rays are
captured within the detector system. Each of these radiographs are
known as single projection and, by rotating the sample through 360°, a
large number of projections are acquired. All of the projections are then
mathematically reconstructed using a suitable algorithm, such as the
FDK algorithm by Feldkamp, Davis and Kress [14], to form a virtual
volume.
The virtual volume produced through XCT is a 3D representation of
the sample, allowing direct measurement of size and shapes of a par-
ticle on micron scales in complex and heterogeneous systems such as
powders [52] along with 3D spatial correlation between different parts
of the sample. Thanks to the above, XCT has already found applications
of pharmaceutical interest. Initially such applications were focused on
tablets: imaging density distributions [59], examining particle move-
ments during compaction [16], and even hydration profiles of caffeine
Table 1
Summary of different techniques currently used for understanding the structure of DPI formulations. ∗Methods which are 2D projections of 3D surfaces are classified
as 2D.
Technique Single species Resolution 2D∗/3D Advantages Disadvantages
Size Shape Roughness
Laser diffraction (LD) ✓ × × 0.5 μm 3D Large numbers of particles can be analysed
very quickly
Assumes spherical particles. Particles need
to be dispersed.
Optical microscopy (OM) ✓ ✓ ✓ 1 μm 2D Quick and easy to use. Readily available. 2D data.
Scanning electron microscopy
(SEM)
✓ ✓ ✓ 10 nm 2D High magnification 2D data.
X-ray computed tomography
(XCT)
✓ ✓ ✓ 2.5 μm 3D Full 3D information on particle attributes and
spatial organisation
Slow acquisition and analysis speed
Fig. 1. The X-ray computed tomography setup involves an X-ray source pro-
ducing a cone beam of X-rays that illuminates the sample. A shadow projection
image (radiograph) is recorded on the detector system, and projections from
different angles can be reconstructed to form a virtual volume.
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and thoephylline anhydrate [46]. It has also been used to study particle
coatings [48], fine granules [45], particle hollowness [28] and the
microstructure of microcrystalline cellulose [12]. Recent developments
in source and detector technology have improved the resolution and
scanning speeds of laboratory machines [38], and coupled with falling
capital costs [29], they have made XCT a more accessible laboratory
technique. As a result, pharmaceutical applications have started to
become more diverse with phase separation in solid dispersions [2] and
drug release over time [21] being studied.
The invaluable powder microstructural descriptors that can be ex-
tracted by XCT along with the spatial relation between particles make
the technique very appealing in the inhalation pharmaceutics field. As
the most common excipient for inhalation formulations, characterising
α-lactose monohydrate is very important. In this work, we characterise
tabletting and inhalation grade lactose using XCT. Tabletting grades
were studied first in order to develop the imaging conditions and image
analysis workflows without the complication of small or non-uniform
particle size distributions typical of inhalation grade lactose. The mi-
crostructure of individual particles within a powder bed is of im-
portance for inhalation formulations, hence the morphology, size and
shape distributions are extracted and compared with scanning electron
microscopy, laser diffraction and optical microscopy to show the ben-
efits of full 3D analysis. Proof-of-concept powder consolidation ex-
periments were also conducted and compared with existing techniques
to show the value of 3D spatial information in understanding flow-
ability at a particle level. With the workflows established, the approach
was extended from the tabletting grades to analyse the more challen-
ging inhalation grade powders.
2. Materials and methods
2.1. Powder preparation
Two commercial tabletting-grade α-lactose monohydrate powders
(CapsuLac 60 and Tablettose 70) were provided from Meggle (Molkerei
MEGGLE Wasserburg GmbH & Co. KG, Germany), whilst inhalation
grade α-lactose monohydrate, namely Lactohale 100 (sieved) and
Lactohale 200 (milled), was provided by DFE Pharma (Goch, Germany).
All powders were analysed as received.
A binary particle blend was prepared consisting of a mixture of
0.133 g Terbutaline Sulphate (TBS) and 1.2 g CapsuLac 60 (mass ratio
1:9) in a 15 ml glass vial. The blending vial was tumbled using a
Turbula shaker-mixer (Willy A Bachofen AG, Basel, Switzerland) at a
frequency of 30 Hz for 1 h.
2.2. Laser Diffraction (LD)
Particle size measurements were performed on a Sympatec HELOS/
RODOS Laser Diffraction (LDA) unit, using the ASPIROS dispersing
system with a dispersing aperture diameter of 4 mm and a feed velocity
of 25 mm s−1 (Sympatec GmbH, Clausthal-Zellerfel, Germany). The R5
lens (measuring range 4.5 μm to 875 μm) was fitted for the measure-
ments. Powder was filled into the ASPIROS glass vials and was dis-
persed via vacuum suction. Airflow titration measurements were per-
formed following a previously established protocol [25]. The primary
pressure (PP) was manually set at 0.2 bar using the adjustment valve
and three measurements were taken using freshly loaded powder.
Particle size distributions were calculated using Fraunhofer theory and
were analysed in WINDOX 5.3.1.0 software, while further analysis was
performed in MATLAB. Particle size measurements for a complete air-
flow titration curve were conducted on a single day.
2.3. Optical Microscopy (OM)
Optical microscopy was used to carry out particle size and shape
analysis of the different powders using a Morphology G3 Particle
Characterization system from Malvern Instruments Ltd.
(Worcestershire, UK). A 26 mm3 sample of each tabletting grade lactose
was dispersed onto a glass plate using the systems automated sample
dispersion unit at a pressure of 0.5 bar. Control of the dispersion
pressure, injection time and settling time ensures high reproducibility
of powder dispersion compared with a manual dispersion method.
Particle imaging was performed using a × 5 magnification lens
(6.5 μm to 420 μm resolution range) to ensure any larger particles or
agglomerates were captured. In order to ensure an even dispersion of
the inhalation grades Lactohale 100 and Lactohale 200 with minimal
touching particles, smaller volumes of 11 mm3 and 7 mm3 were used
respectively together with a dispersion pressure of 2.0 bar. The auto-
mated image analysis captures a two dimensional (2D) image of a 3D
particle projected on the glass plate and calculates various size and
shape parameters from the 2D image. The size and shape distributions
were derived by combining the results for every particle in the sample.
The particle size distribution was measured using Circle Equivalent
(CE) diameter, namely the diameter of a circle with the same area as the
2D image of the particle. The number-based size distribution was
converted to volume-based distribution using volumes of spheres with
the measured diameters. The shape was characterised by the aspect
ratio and circularity. The aspect ratio is given by the ratio of the
shortest distance to the longest distance in the image of the particle,
whilst circularity (Eq. (1)) is the 2D equivalent of the sphericity (Eq.
(2)) and is given by the weighted ratio of the particle area A to the
perimeter P:
= A
P
circularity 4 . (1)
2.4. Scanning Electron Microscopy (SEM)
The powders were deposited onto adhesive carbon tabs (Agar
Scientific G3357N), which were pre-mounted onto aluminium stubs
(Agar Scientific JEOL stubs G306) and then sputter-coated with gold for
1 min to achieve a thickness of around 30 nm (Quorum SC7620) in
order to reduce electrostatic charging. The images were acquired using
a JEOL 5700 scanning electron microscope, operated at 20 kV and a
working distance of 10 mm.
2.5. X-ray computed tomography (XCT)
A sample mount for XCT was created by gluing 3 mm diameter
Kapton (polyamide) tubing of length 25 mm onto a nail. Each powder
plug was prepared by filling a separate sample mount with powder
using a spatula, before gluing a small piece of paper on the top to seal
the tube. Scans were performed at the Henry Moseley X-ray Imaging
Facility using a Zeiss Xradia Versa 520 cabinet X-ray microtomography
system, with the acquisition parameters given in Table 2. The Versa
family of instruments are particularly suited to scanning low density
powders, as the detector system uses X-ray optical lenses for magnifi-
cation, allowing small working distances that minimise the absorption
loss in air. In addition, the coherent source within the Versa family
allows in-line X-ray phase contrast that is useful in the segmentation
[40]. Virtual volumes for each sample were computationally re-
constructed from the projection images using the native Zeiss re-
construction software. The voxel size of the reconstructed volume is
equal to the acquisition pixel size cubed, with the minimum resolvable
feature being ~3 × the voxel size.
A single slice through a virtual volume of a CasuLac 60 powder bed
is shown in Fig. 2A. There are distinct greyscale values for two phases
present, with the denser lactose having brighter pixels and the less
dense air having darker pixels. The coherence of the source, small
working distances and low density material all combine to produce in-
line phase contrast, with identifiable phase fringes at the edges of the
particles. A zoomed-in section of the same slice is provided in Fig. 2B,
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which shows a very bright ring around the inside boundary edge of the
particle and a dark ring around the outside boundary edge.
The data was filtered using an edge-preserving filter such as a bi-
lateral filter or a 2D non-local means, and the lactose separated from
the air using a global automatic greyscale thresholding as shown in
Fig. 2C. In order to separate the individual grains, a binary image was
produced of the particle edges, with the phase fringes producing a sharp
morphological image gradient. Morphologically combining the phase
fringes with the lactose mask created marker labels for each particle,
which were expanded out to each fill each particle using a watershed
algorithm [68]. This produced a labelled image in which all of the
voxels of an individual particle are assigned the same integer value, as
can be seen in Fig. 2D.
This approach for creating marker labels is different from the
common approach of using distance maps [69], where each pixel within
the particle is assigned a value according to its euclidean distance from
the edge of the particle. The distance map method works well for
spherical grains since the centre of a sphere is a local maximum of the
distance from the edge of the grains. However, for the non-spherical
lactose grains, the distance map could be seen through visual inspection
to consistently over-segment particles [3], i.e. excessively separating
particles so that they were too small. Instead the X-ray phase contrast
Table 2
XCT scanning parameters used on a Zeiss Xradia Versa 520 microtomography system for the different sample types.
Sample Voltage (kV) Power (W) Exposure (s) Projections Binning
Mode
Objective Lens Source distance
(mm)
Detector distance
(mm)
Pixel Size
(μm)
CapsuLac 60,
Tablettose 70
(Characterisation)
80 7 3.5 3201 1× 4× 12 14 1.56
CapsuLac 60,
Tablettose 70
(Tap Density)
120 10 0.8 1601 2× 4× 27 19 4.00
Lactohale 100,
Lactohale 200
80 7 3.5 3201 1× 10× 12 14 0.64
Terbutaline sulfate (10% w/w)
Blend
40 3 12.5 1601 2× 10× 12 14 1.27
Fig. 2. (A) A single horizontal slice through the virtual tomographic volume of CapsuLac 60. (B) α-lactose monohydrate exhibits phase contrast when scanned, with a
bright ring inside the particle boundary edge and a dark ring outside the boundary; (C) Lactose segmented from air; (D) All particles separated and shown with a
different colour per particle, with this slice containing 176 unique particles.
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fringes provide contrast between lactose and air, and were exploited to
provide confident differentiation between particles that are more than
one pixel-width apart (Table 2). For reference, the pixel-size for scans of
tabletting grades and inhalation grades was 1.56 μm and 0.64 μm re-
spectively. Visual inspection showed that the phase contrast approach
provided a better segmentation than the distance map approach,
without under- or over-segmenting the grains.
The labelled image can be processed to produce volume, size and
shape measurements for each particle. The volume of a particle is
simply the summation of all voxels assigned to that particle, which can
also be used to give the particle size as the diameter of a sphere with an
equivalent volume. The three-dimensional representation gives three
distinct lengths, namely eigenvalues of the moments of inertia matrix of
the particle known as length, breadth and width in decreasing order of
magnitude. Taking pairs of these gives three aspect ratios [58]. The
sphericity is a measure of how spherical a particle is, and is defined as
the ratio of the surface area of an equivalent volume sphere Seq to the
actual 3D surface area of the particle S, i.e.
= =
S
S
V
S
sphericity (6 ) ,eq
1/3 2/3
(2)
where V is the actual particle volume.
2.6. Powder densification and consolidation
Powder densification studies were performed using XCT and a
Copley Tap Density instrument. The tap density measurements on the
Copley instrument were performed by pouring 10 g of powder into a
25 ml volumetric cylinder and noting the volume before and after 1000
taps. The measurements were performed in triplicate and the experi-
mental error was ± 0.25 ml. The XCT densification was measured
through a series of scans using larger 14 mm diameter Kapton tube to
prevent fluidisation, with a 4 mm cubic region of interest at the bottom
of the tube. The tube was filled with powder using a funnel up to a
height of 42 mm (approx. 6.5 ml) and the first scan performed. The
entire sample holder was then tapped by hand 500 times and a second
scan performed. Different scanning parameters were used due to the
larger amount of material for the X-rays to pass through, which are
given in Table 2. In order to calculate the density from the virtual vo-
lumes, the first 40 slices were removed from the top and bottom of the
final volumes due to cone beam artefacts. As in Section 2.5, the virtual
volumes were filtered and global thresholding used to identify lactose
voxels. The total number of lactose voxels was sufficient for the tap
density, as the number is directly proportional to the volume of lactose
within the imaged volume that is constant for both scans. The amount
of lactose can be expressed as a volume fraction (VF), from which Carr’s
index can be calculated as:
= ×Carr's index 100 1
VF
VF
.pre tap
post tap (3)
An alternative measure of flowability is the Hausner Ratio, which can
be calculated as:
=Hausner ratio VF /VF .post tap pre tap (4)
2.7. Ring shear testing (RST)
The ring shear testing technique was applied for the evaluation of
the flow properties of the powder samples. Each measurement was
performed using the ring shear tester, RST-XS (Dietmar Schulze,
Germany). At the beginning of the measurement, the powder sample
was filled into a 30 ml annular shear cell without applying force to the
upper surface of the powder bed. The powder was then consolidated
under a pre-shear normal consolidation stress of 2 kPa and the lower
portion of the cell was slowly rotated until a steady state flow had been
achieved. After the pre-shear process, the normal stress was first re-
leased and a lower normal stress was then applied to shear the powder
until the incipient flow occurred in the powder sample. The incipient
shear stresses were measured at three different normal stresses (0.4, 1.0
and 1.6 kPa). A yield locus was constructed for each powder and the
respective flowability index (ffc) was calculated using the instrument
software. The results were repeated for pre-consolidation stresses of
5 kPa and 10 kPa.
Fig. 3. Morphology of the tabletting lactose grades produced through XCT (A & B) and SEM (C & D). The XCT images are coloured with a different colour for each
separated particle. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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3. Results
3.1. Tabletting grades
3.1.1. Particle morphology
The final segmented volume, containing virtual representations of
every particle, provides a wealth of 3D information. Three-dimensional
visualisations allow the complete particle morphology to be assessed, as
shown in Figs. 3A and B with each separated particle represented by a
unique colour. SEM is a commonly used technique for assessing mor-
phology, and SEM images of a corresponding scale are shown below in
Fig. 3C and D. CapsuLac 60 is a sieved grade that is known to contain
individual single crystals, with some agglomerates. This can be seen in
the XCT morphology in Fig. 3A with many crystals showing typical
lactose “tomahawk” shapes with clear facets. On the other hand, Fig. 3B
shows Tablettose 70 to have a more rounded structure, which is con-
sistent with the manufacture of the powder through continuous spray
dry agglomeration. The XCT shows more agglomeration than the SEM
images. This is likely due to the dispersion needed to prepare the sus-
pension on the SEM slide, which would break up weakly connected
particles. The 3D void space ( ) between particles can be further
quantified by XCT with results given in Table 3.
3.1.2. Particle size distribution
Beyond simple visualisation, the virtual particle representations can
be used to quantify the particle size and shape. By summing the voxels
of that particle, XCT calculates its actual volume without any a priori
assumptions. This is in contrast to LD, which assumes that particles are
spherical with a specified adjustment factor, and to OM/SEM, which
calculates the volume of a sphere with an equivalent diameter to that of
the projected area. Note that OM is more routinely used for size analysis
than SEM due to the lower magnification, lack of coating and auto-
mated workflows of machines such as Morphologi G3 (Malvern, UK).
The number of unique particles within the sampled volume for XCT was
5120 and 12976 for CapsuLac 60 and Tablettose 70 respectively, whilst
the corresponding number of sampled particles for OM were 4609 and
11262. A comparison of the particle size-distributions produced by the
LD, XCT and OM is shown in Fig. 4, with a non-logarithmic x-axis used
to highlight differences in the distributions. The shape of the distribu-
tions are broadly similar across the methods, which provides confidence
that the segmentation method is neither systematically under-seg-
menting nor over-segmenting the particles. Whilst visual inspection
shows locally on single cross-sectional slices whether the image analysis
method is under-segmenting or over-segmenting, the size-distribution
gives a meso-scale reference over all of the particles. In the case of
under-segmentation, the XCT curve would be shifted significantly to the
right compared to LD and OM, whilst case of over-segmentation the
XCT curve would be shifted significantly to the left. However it is found
that the XCT curves show good overlap with the other methods for all of
the powders examined thus validating the quality of segmentation.
Looking more closely, the XCT distribution is narrower and has a
slightly lower modal value for both powders compared to LD and OM.
This can also be appreciated by examining the 10th (D10), 50th (D50)
and 90th (D90) percentiles of particle size in Table 4. The lower modal
and percentile values for XCT are due to it measuring the actual volume
of the particle. On the other hand, the assumption of particle sphericity
used in both LD and OM means that the reported sizes are overestimates
of the actual particle sizes [62]. This is the main reason that the XCT
distributions lie to the left of LD and OM, rather than being due to the
resolution limits of either technique. It is also noteworthy that whilst
the XCT and LD statistics are broadly comparable, those of OM are of
the order of 20 μm larger. This is because the size distribution is based
on a single 2D projection of the particles, and can vary significantly
depending on the direction imaged. This also has a significant impact
on the particle shape analysis. The XCT size distributions show a sig-
nificant right-hand tail, which is likely to be due to the presence of
aggregates that would not be separated as there is no dispersion in the
powder preparation.
3.1.3. Particle shape distributions
A comparison of aspect ratio and sphericity distributions for both
tabletting grade powders can be found in Fig. 5. The length to breadth
and breadth to width ratios broadly coincide, whilst the length to width
ratio is much lower reflecting the classical tomohawk shape of lactose.
This information cannot be found in the aspect ratio distribution pro-
duced by static imaging, where the 2D projections permit only two
independent lengths, and hence one aspect ratio to be determined
which coincides with both length-to-breadth and breadth-to-width ra-
tios.
The sphericity/circularity distributions in Fig. 5 show a much more
distinct difference between OM and XCT, which can be attributed to the
difference between 2D and 3D imaging. Fig. 5B shows the sphericity/
circularity for CapsuLac 60, with OM giving a broad distribution that is
nearly uniform between 0.6 and 0.9. An explanation for this could be
due to differences in imaging a particle from different orientations.
Consider the single particle in Fig. 6, shown in two different orienta-
tions with the corresponding 2D projection underneath. The orientation
in Fig. 6a has a circularity of 0.67, whilst the orientation in Fig. 6b has a
circularity of 0.89. DEM simulations of different particle settling under
gravity (supplementary video V1) showed that the 2D circularity can be
± 8% compared to the 3D value [7]. Thus, as the 2D circularity can vary
by 15% for each particle, imaging over 5000 particles can yield a broad
distribution. By contrast, the XCT displays a thin normal-like distribu-
tion with a mode of approximately 0.8, as each particle only has a single
sphericity. For example the particle shown in Fig. 6 has a sphericity of
0.79. The sphericity of the tomahawk shape predicted by synthon-based
modelling is 0.87 [44].
There is a clear lower tail to the XCT distribution of CapsuLac 60 in
Fig. 5B, with a small number of particles having sphericities between
0.3 and 0.6. The lower sphericity is a result of the agglomerated
structure. Tablettose 70 is known to have a high proportion of ag-
glomerates, and this can be seen in its sphericity distribution in Fig. 5D
with a smaller lower peak around 0.5. Although OM also gives a bi-
modal distribution, the lower peak is around 0.65 and is a high pro-
portion compared to XCT.
3.1.4. Powder density and flowability
One further property that is important for inhalable powders is their
flowability, which can be quantified using the Carr’s index or Hausner
ratio. A comparison between XCT and a benchmark of a Copley tap
density instrument can be found in Table 5. Both techniques show si-
milar results, with CapsuLac 60 showing both a slightly lower Carr’s
index and slightly lower Hausner ratio than Tablettlose 70, implying
marginally better flowability that Tablettose 70. This can be linked
back to the size and shape distributions in Figs. 4 and 5 with both
powders having similar modal sphericities, but CapsuLac 60 having a
larger particle size and hence lower granular Bond number [6].
Quantatively, the Carr’s index and Hausner ratio calculated from XCT
are larger than those of the Copley tap density instrument. As this was a
proof of concept experiment to study the process of powder densifica-
tion of relevance to powder flow, it should be noted there were a
number of experimental factors that would contribute to the differ-
ences: 1) the initial poured state was less for XCT than for the Copley
Table 3
3D measurements of the void fraction (defined as the ratio of void volume to
total analysis volume) from XCT, for each of the tabletting and inhalation
lactose grades. Lactohale 100 and Lactohale 200 abbreviated as LH100 and
LH200 respectively.
CapsuLac 60 Tablettose 70 LH100 LH200
0.562 0.548 0.402 0.409
P. Gajjar, et al. European Journal of Pharmaceutics and Biopharmaceutics 151 (2020) 32–44
37
instrument; this would affect the final tapped state and hence Carr’s
index and Hausner ratio; 2) The volume of powder examined in XCT
was less than with the Copley instrument; 3) The smaller diameter tube
used in XCT compared to Copley means that wall effects may have more
influence. As there are multiple contributing factors, a direct compar-
ison with the Copley instrument was not appropriate, although it was
possible to conclude that powder densification could be studied by XCT,
analogous to the tap densitometry, albeit requiring substantially lower
material sample mass.
The RST results in Fig. 7A are consistent with the tap density results
in showing that both CapsuLac 60 and Tablettose 70 are free-flowing. In
general, the greater the ffc value, the more free-flowing the powder is,
with powders having >ff 10c considered to be free flowing. Further-
more, CapsuLac 60 is more free flowing at low pre-consolidation
stresses, but Tablettose 70 is marginally more flowable at high pre-
consolidation stresses. This can be linked to the particle size and shape
analysis of the two powders in Sections 3.1.2 and 3.1.3 through the bulk
cohesion and angle of friction shown in Fig. 7B. CapsuLac 60 has a
lower bulk cohesion, which can be explained through its larger particle
size [56]. The friction angle for CapsuLac 60 decreases with pre-con-
solidation stress, whereas for Tablettose 70, it initially increases. This
could be related to the non-spherical aggregates in Tablettose 70 that
have a lower sphericity, and could prevent flow through interlocking
[1].
One clear advantage of XCT is that it allows the densification and
flowability to be examined in 3D, with the ability to see changes in void
spaces and particle orientations. Fig. 8 shows a vertical cross-sectional
slice taken at the same location of the Kapton tubing containing
CapsuLac 60 and Tablettose 70 before and after tapping. The pre-tap
state of both powders shows many large air pockets between particles,
and although the post-tap states shows smaller void spaces between the
particles, there are still a small number of larger void spaces. This
would suggest that further densification is possible with more tapping,
which is consistent with the lower final tapped density in XCT as
compared to the Copley instrument. Qualitatively, Tablettose 70 ap-
pears to have fewer of these large air pockets in the tapped state,
suggesting that it is closer to its final steady state. It would also be
possible to examine spatial changes in size distribution during the
densification process, but this lies outside the scope of these proof of
concept studies.
3.2. Inhalation grade lactose
Inhalation grade lactose presents a bigger challenge due to its
higher complexity and smaller particle sizes, however the same method
can be applied. Visualisations of Lactohale 100 and Lactohale 200 can
be seen in Fig. 9A and B respectively. Visual inspection shows the dif-
ference between the sieving and milling processes, with Lactohale 200
showing a higher number of intrinsic lactose fines than Lactohale 100.
The number of fines can be quantified in the size distribution shown in
Fig. 9C. As the maximum standard deviation between the 3 LD repeats
across all sampling points was less than 0.75%, error bars were of the
same order of magnitude as the line width and hence are omitted from
Fig. 9C to allow a clearer comparison between XCT and LD. The number
of analysed particles for XCT was 4894 and 30855 for LH100 and
LH200 respectively. Both Lactohale 100 and Lactohale 200 have main
peaks around 100 μm corresponding to the coarse lactose, with Lacto-
hale 200 showing a second smaller peak around 20 μm corresponding
to lactose fines. The number density of lactose fines can also be quan-
tified through XCT by splitting the analysis region into 8 smaller cubes
of side length 300 μm and counting the number of lactose fines in each
cube. This gave mean densities of lactose fines as ±9426 559 particles
per mm3 and ±66458 6033 particles per mm3 for Lactohale 100 and
Lactohale 200 respectively. It is also important to know the spatial
position of fines within the entire powder bulk, and this is visualised in
Fig. 9D with lactose fines less than 12 μm shown in yellow and those
greater than 12 μm shown in grey. A video of the positions of lactose
fines in Lactohale 200 can be found in Supplementary Video V2.
Dry powder inhaler formulations also contain fine API particles
together with the excipient lactose, and Fig. 10 shows a cross section
through the virtual volume and a 3D visualisation of an XCT scan of a
representative blend of CapsuLac 60 and TBS. Despite CapsuLac 60
being a larger and more simple powder compared to the Lactohale
Fig. 4. Comparisons of the size distributions for the two tabletting grades produced using the X-ray computed tomography (XCT), laser diffraction (LD) and optical
microscopy (OM).
Table 4
Size distributions statistics (defined in text) for tabletting grade and inhalation
grade lactose produced from X-ray computed tomography (XCT), laser dif-
fraction (LD) and optical microscopy (OM). All measurements are given in
microns. †The inhalation grades were dispersed at 2.0 bar for the OM mea-
surements.
D10 D50 D90 D10 D50 D90
CapsuLac 60 Tablettose 70
XCT 165 251 367 113 165 256
LD 169 262 357 113 187 298
OM 183 270 367 128 183 278
Lactohale 100 Lactohale 200
XCT 49 93 121 19 67 109
LD 55 124 205 11 67 128
OM† 58 152 242 25 92 149
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grades, the representative blend highlights the complex nature of in-
halation blends. Although CapsuLac 60 and TBS have differences in
particle size and small differences in atomic density, Fig. 10A shows
how there is very little discernible difference between the grayscale
values of the two species. As a result, it is not currently possible to
segment the two phases with confidence using absorption contrast and
Fig. 10 does not make any attempt to differentiate between the species.
Further work is currently under way to utilise phase contrast (Fig. 2B,
Mayo et al. [40]) to distinguish between the different species.
4. Discussion
X-ray computed tomography has been widely used for character-
ising particulate materials, ranging from large rocks in the mining in-
dustry [42] to additive manufacturing powders [60], however the
challenge in using XCT for DPI formulations is the small particle size
and low atomic density. In this paper, we have shown how XCT can
provide invaluable three-dimensional insight into the structure of
pharmaceutical powders. In particular, the particle morphology, bulk
powder void fraction, particle size and shape distributions, and tap
Fig. 5. Comparison of the aspect ratios and sphericity distributions for the two tabletting grades using the X-ray computed tomography (XCT) and optical microscopy
(OM). Points a and b in B correspond to the 2D circularity results of a single particle projected in two different orientations, as shown in Fig. 6a,b respectively.
Fig. 6. Imaging a single particle from two different orientations, a and b can
give circularity values of 0.67 and 0.89 respectively. For comparison, the 3D
sphericity value calculated from XCT for this particle is 0.79.
Table 5
Comparison of tap density results between XCT and a Copley tap density
system.
CapsuLac 60 Tablettose 70
CT Poured Density (g ml−1) 0.47 0.46
Tapped Density (g ml−1) 0.54 0.53
Carr’s index 13.1 14.3
Hausner ratio 1.15 1.17
Copley Poured Density (g ml−1) 0.61 0.53
Tapped Density (g ml−1) 0.66 0.59
Carr’s index 6.5 10.2
Hausner ratio 1.08 1.11
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density measurements were collected for a tabletting grade lactose,
with inhalation grade lactoses and a blend also analysed.
The particle morphology could be judged from a 3D rendering of the
segmented data, and compared to SEM images of the same magnifica-
tion. Although SEM images allow higher magnification from a single
projection angle, the advantage of XCT is that it allows the powder to be
examined from any desired angle with the minimum of sample pre-
paration, i.e. without dispersion and with no gold coating. Correlative
techniques for combining the 3D results of XCT with the magnification
of electron microscopy results have been developed for metallic coat-
ings [4], but an extension to free powder beds requires the development
of a resin for fixing the bulk powder without altering the surface or
internal structure.
Volumetric void fractions were easily calculated for each of the
powder grades, and furthermore the void spaces can also be easily vi-
sualised. This could provide a useful connection between fluidization
Fig. 7. (A) Flow function coefficients (ffc) for CapsuLac 60 (solid line and circular markers) and Tablettose 70 (dashed line and square markers). (B) Bulk cohesion
and angle of friction for the two powders using the same respective linestyles.
Fig. 8. Vertical cross sectional slices from virtual XCT volumes of CapsuLac 60 (A,B) and Tablettose 70 (C,D) showing the initial particle density (A,C) and the
densified state following 500 taps (B,D). The lactose particles are highlighted in red and the scalebar in A is applicable to all images. Gravity is downwards.
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Fig. 9. 3D renderings of two inhalation grades show the difference between sieving (Lactohale 100 shown in A) and milling (Lactohale 200 shown in B) processes,
with one colour per particle. Size distributions for the two grades from XCT and LD are shown in C, with fine lactose of size <12 µm highlighted in grey. The
visualisation in D is the same data and orientation as B but shows the relative positions of the fine lactose (<12 µm) in orange and coarser lactose (>12 µm) shown in
grey. A video of D can be seen in supplementary material video V2.
Fig. 10. A horizontal cross sectional slice (A) and 3D rendering (B) of a representative blend of CapsuLac 60 and Terbutaline Sulphate highlighting the complexity of
inhalation formulations.
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and aerosolization simulations [33] and experiments [66], for instance
by scanning the experiment to determine the exact initial particle ma-
trix as the starting conditions for simulations. The combination of XCT
and simulations would also open new avenues for understanding the
behaviour of DPI powder blends, for instance how the initial particle
orientation and packing affect the aerosolisation behaviour.
It was seen that XCT produces size distributions comparable to laser
diffraction and static imaging; the slightly lower sizes are a result of
using all of the volumetric information of the particle with no prior
assumptions. Even if XCT results are taken to be a more accurate de-
termination of size, laser diffraction is still a more widely available
industrial technique and a very fast method for size analysis. The
comparable distributions give confidence that laser diffractions remains
a good choice for size analysis, but work is underway to further improve
LD distributions by feeding shape information from XCT into the LD
non-sphericity adjustment factor.
Although size distributions were comparable between XCT and the
other methods, the shape distributions produced from the 3D XCT data
provided more accurate measures of the aspect ratio and sphericity than
2D static imaging. Indeed, the pitfalls of basing shape distributions from
single 2D projections of particles are clearly shown with projections of a
single particle. For this reason, XCT presents a clear alternative for
accurate shape analysis. It should also be noted that shape and size
analysis are performed in tandem on the same bulk powder, allowing
cross correlations to be accurately determined. Further work is un-
derway looking to advance the shape analysis by deriving shape factors
correlated to predicted crystal geometry, along with determining how
the shape affects the surface properties and binding to micro-lactose
and API particles.
When comparing LD, OM and XCT, it is worth considering the dif-
ferent availabilities and scan times. Both LD and OM instruments are
commonly found throughout both industrial and academic laboratories
and allow analysis of multiple samples within several hours. Most LD
and OM systems have automated work flows that require only basic
user training. On the other hand, XCT systems with the highest re-
solution of<1 µm needed for examining inhalation powders have much
more limited availability, and can take approximately 4-5 h to scan
each sample. Furthermore, XCT systems currently require technicians
experienced in both instrument operation and image processing in
order to extract quantitative powder information. Relatively speaking,
there is still a large capital and knowledge barrier to pharmaceutical
industry use of XCT, as compared to LD and OM. Initiatives in the UK
such as establishment of the Future Continuous Manufacturing and
Advanced Crystallisation Research Hub1 and the Henry Royce Institute
for Advanced Materials2 are helping to bridge the gap between uni-
versities and industry by making cutting edge material science instru-
ments and expertise accessible to those outside academia [30].
The effect that powder microstructure has on performance is also
important, and one aspect of inhalation powder performance is flow-
ability. Particle size and shape affect the flowability, in turn affecting
the emission and drug loss [27]. Flowability is intrinsically linked to
particle organisation, and the proof of concept tap density studies show
the potential of XCT for 3D analysis of flowability. A simple compres-
sibility index such as Carr’s index or Hausner ratio gives no insight on
particle organisation, and although flow function coefficient curves
provide a relation between particle size, shape and flowability, they too
do not allow the flow behaviour to be visualised at the particle level.
The proof of concept experiments demonstrate how XCT allows such
visualisation, also providing information on particle interconnectivity,
and whether particle orientations also change during tapping [67].
Scans would need to be optimised for image resolution rather than
speed, and a more systematic tapping or flowing mechanism
synchronised with the XCT machine would allow motion between taps
to be resolved [17]. A systematic tapping mechanism would also allow
a more equivalent comparison to standard tap density instruments.
XCT was also shown to be valuable analytical technique for smaller
sized and more complex inhalation powders, distinguishing clear
morphological differences between sieved Lactohale 100 and milled
Lactohale 200. As with tabletting grades, XCT could also produce par-
ticle size distributions of the inhalation grades that are comparable to
LD. In addition XCT could produce number densities of lactose fines,
and also highlight their spatial positions in 3D, which is not available
through any other technique. Work is currently under way to utilise this
strength of XCT to examine the effects of manufacturing processes on
the number and position lactose fines, and in addition, to extend the
method to work with blends of carrier lactose and fine API particles.
The performance of an inhaler is fundamentally dependant on the
aerodynamic behaviour of the particles, which is linked to the particle
size, shape and interfacial interactions. Yet there is currently only a
limited understanding of the relationships between material properties,
microstructure, particle size, and powder performance [57]. In pro-
viding a direct link between size, shape, and performance attributes
such as flowability, XCT has the potential to give real insight into the
aerosolisation process that generates the potentially-inhalable aerosol
cloud. Aerosol formation from a DPI is governed by the interaction
between the inhalation airflow and a powder bed that possess a me-
chanical resistance to aerosolisation due to its microstructure. XCT
provides the ability to study an inhalation powder’s microstructure, and
to begin to de-construct the aerosolisation process. Building on the
simple DEM gravity settling experiments in this manuscript, more ad-
vanced DEM simulations are currently under way that utilise real 3D
shapes to predict the behaviour of a bulk powder through a device and
into an inhaled air stream.
Alongside the benefits of full 3D analysis, the non destructive nature
of XCT makes it an important tool for examining new and potentially
expensive formulations. No new DPIs have entered the market in the
past 20 years, with one of the aims of future DPIs being low cost [10]. In
this regard, the ability of XCT to measure size and shape from only a
small amount of material and simple sample preparation whilst al-
lowing that material to be reused in other tests should help improve
development processes and efficiency. XCT offers benefits for early drug
development phases, when API is typically in scarce supply, and could
facilitate rapid decision-making early in development cycles. XCT could
also be used to analyse powder blends within capsules or DPIs, and
could even be utilised as a process-line tool for quality assurance.
All of this current work and future avenues are brought together by
the INFORM2020 consortium, a partnership between five UK uni-
versities, pharmaceutical companies and technology specialists to im-
prove our understanding of drug deposition performance from mole-
cular scales up to inhaler manufacture. The information provided by
XCT is complementary to many of the work packages, from synthonic
modelling of carrier and DPI crystals to simulations of the aerosolisa-
tion process within an inhaler. Together, these will help develop the
next generation of inhaled therapy products.
5. Conclusion
Given how central powders are to the functionality and performance
of DPIs, accurate characterisation of powder micro-structure is of very
high value. In this paper, we have demonstrated for the first time how
X-ray computed tomography (XCT) can be an analytical characterisa-
tion tool for inhaled therapy powders, producing number- and volume-
based particle size distributions, shape distributions, and morphological
assessment.
We have shown how XCT can inform the powder morphology in a
similar fashion to scanning electron microscopy, with lower resolution
but with the added value of 3D. Size distributions were comparable
between XCT, laser diffraction (LD) and optical microscopy (OM),
1 https://www.cmac.ac.uk/
2 https://www.royce.ac.uk/
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although XCT were marginally lower due to the fully 3D measurements.
Shape distributions were different between XCT and OM, showing the
importance of 3D imaging compared to 2D. Proof of concept experi-
ments also showed how XCT can give unique 3D spatial insight into
how particle attributes such as size and shape affect the particle ar-
rangements and hence the flowability, with many aspects of micro-
structure and organisation of the formulations accessible through XCT
which are not possible through other methods. Going forwards auto-
mated data analysis tools will reduce the skill level and the reprodu-
cibility of XCT analyses.
Through this work, we have clearly shown that XCT can be an in-
valuable, fully 3D and non-destructive powder characterisation tech-
nique that has a number of advantages for characterisation of inhala-
tion therapy blends.
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